- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07944092
Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors (ENGAGE)
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of FMC-242 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are:
Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses?
Participants will need to come to the clinic to have the following:
- Physical exams to see if there are any side effects
- Standard lab tests to observe blood counts and other values
- ECGs to measure heart signals
- Blood drawn to measure how the drugs are being metabolized
- Imaging such as CT scans to monitor if the cancer is growing or not
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a first-in-human, Phase 1/2, open-label, multi-center dose escalation and expansion study to evaluate the safety, tolerability, PK, and anti-tumor activity of FMC-242 monotherapy and in combination in participants with locally advanced or metastatic solid tumors. FMC-242 is in a new class of drugs called PI3Kα:RAS breakers. The combination escalation cohorts may enroll while the monotherapy portion is still determining MTD/recommended dose for expansion (RDE).
This study is being conducted in two phases:
Phase 1 Dose Escalation: to determine the MTD and/or preliminary RP2D(s) and dosing regimen of FMC-242 monotherapy and in combination.
Phase 2 Cohort Expansion: to evaluate the efficacy and safety of FMC-242 at the RP2D(s) as a monotherapy and in combination in disease-specific cohorts.
After consenting to participate, participants will complete screening assessments during a Screening Period. Eligible participants will receive FMC-242 orally, at approximately the same time each day.
Depending on the tumor type, participants in combination cohorts will also receive the addition of another cancer drug administered per the local prescribing information/investigational labeling.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Aaron (Ron) Weitzman, CMO, MD
- Número de teléfono: 650-457-1005
- Correo electrónico: clinicaltrials@frontiermeds.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Males and females of age ≥ 18 years at the time of signing the informed consent document.
- No known downstream mutations in the AKT or RAS pathway
- Measurable disease per RECIST v1.1.
- Documented disease progression on, or disease recurrence after at least 1 line of standard of care (SoC) systemic treatment, including approved targeted therapy for patients with actionable mutations, or, in the opinion of the Investigator, would not be able to tolerate SoC therapy, or refused SoC therapy.
- Eastern Cooperative Oncology Group performance status 0-1.
- Adequate hematological, renal, and hepatic function.
- In Phase 1 only, must be willing to provide an on treatment tumor biopsy provided it is safe and medically feasible.
- Women and men of child-bearing potential must agree to use highly effective contraceptive methods.
- Willing and able to adhere to the study visit schedule and other protocol requirements.
- Has an archival tissue for retrospective confirmatory testing, unless discussed with the study Medical Monitor.
Exclusion Criteria:
- Prior use of a PI3Kα:RAS breaker (e.g., BBO-10203, VVD-159642).
- Prior use of a RAS inhibitor (either pan-RASi or isoform-specific)
- Received any systemic anti-cancer therapy or investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug.
- Received radiation within 14 days prior to the first dose of study drug.
- Clinically significant toxicity resulting from prior cancer therapies that have not returned to baseline or ≤ Grade 1
- Known, uncontrolled central nervous system (CNS) metastases.
- History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
- Prior malignancy, requiring treatment or intervention, within the previous 3 years of study drug dosing, except for appropriately treated local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, which are allowed.
- Pregnant or breastfeeding.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: FMC-242 Monotherapy
FMC-242 alone |
PI3Kα:RAS breaker |
|
Experimental: Combination Cohort A
FMC-242 in combination with trastuzumab |
PI3Kα:RAS breaker HER2 targeting agent
Otros nombres:
|
|
Experimental: Combination Cohort B
FMC-242 in combination with fulvestrant |
PI3Kα:RAS breaker selective estrogen receptor degrader
Otros nombres:
|
|
Experimental: Combination Cohort C
FMC-242 in combination with a Pan (K)RAS inhibitor |
PI3Kα:RAS breaker Pan (K)RAS inhibitor |
|
Experimental: Combination Cohort D
FMC-242 in combination with FMC-376 |
PI3Kα:RAS breaker KRAS G12C inhibitor (experimental) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Phase 1 and Phase 2: Adverse Events
Periodo de tiempo: Approximately 24 months
|
Number and grade of adverse events (AEs) with FMC-242 alone and in each of the combinations using CTCAE v 6.0 |
Approximately 24 months
|
|
Phase 1 : Dose Limiting Toxicities
Periodo de tiempo: Up to 21 or 28 days
|
Number of dose limiting toxicities (DLTs) with FMC-242 alone and in each of the combinations |
Up to 21 or 28 days
|
|
Phase 2: Overall Response Rate
Periodo de tiempo: Approximately 24 months
|
Assess the overall response rate (ORR) using RECIST 1.1 in participants treated with FMC-242 alone and in each of the combinations |
Approximately 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Phase 1: Assess anti-tumor activity
Periodo de tiempo: Approximately 24 months
|
To assess preliminary anti-tumor activity of FMC-242 alone and in combinations using RECIST v1.1 |
Approximately 24 months
|
|
Phase 1: FMC-242 Maximum observed plasma concentration
Periodo de tiempo: 6 weeks
|
Measure the maximum observed plasma concentration (Cmax) for FMC-242 |
6 weeks
|
|
Phase 1: FMC-242 time to maximum observed plasma concentration
Periodo de tiempo: 6 weeks
|
Measure time to maximum observed plasma concentration (Tmax) for FMC-242 |
6 weeks
|
|
Phase 1: FMC-242 trough observed concentration
Periodo de tiempo: 6 weeks
|
Measure trough observed concentration (Cmin) for FMC-242 |
6 weeks
|
|
Phase 1: Area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval
Periodo de tiempo: 6 weeks
|
Measure area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval (AUC0-t, AUCtau) for FMC-242 |
6 weeks
|
|
Phase 1: Terminal half-life
Periodo de tiempo: 6 weeks
|
Measure the terminal half-life (t1/2) for FMC-242 |
6 weeks
|
|
Phase 1: Apparent clearance
Periodo de tiempo: 6 weeks
|
Determine apparent the clearance (Cl/F) for FMC-242 |
6 weeks
|
|
Phase 1: Determine the volume of distribution
Periodo de tiempo: 6 weeks
|
Determine volume of distribution (Vd/F) for FMC-242 |
6 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Aaron (Ron) Weitzman, MD, Frontier Medicines
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Aminoácidos, péptidos y proteínas
- Proteínas
- Compuestos policíclicos
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Esteroides
- Compuestos de anillo fusionado
- Estradiol
- Estreness
- Estranos
- Congéneres de estradiol
- Hormonas esteroides gonadal
- Hormonas gonadales
- Productos biológicos
- Mezclas complejas
- Trastuzumab
- Fulvestrant
- Farmacéuticos biosimilares
Otros números de identificación del estudio
- FrontierMed
- 2026-528809-31-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Aggregate study data will be shared at the end of the study.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .